1 / 47

Plasma Cell

Plasma Cell. Disorders. Monoclonal Gammopathies. Kristi McIntyre M.D. Texas Oncology 2004. Classification of Monoclonal Gammopathies. Monoclonal Gammopathy of Undetermined Significance

tuan
Download Presentation

Plasma Cell

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Plasma Cell Disorders Monoclonal Gammopathies Kristi McIntyre M.D. Texas Oncology 2004

  2. Classification of Monoclonal Gammopathies • Monoclonal Gammopathy of Undetermined Significance • Malignant Monoclonal Gammopathies Multiple Myeloma Smolderimg Multiple Myeloma Plasma cell leukemia IgD myeloma POEMS • Plasmacytoma • Malignant Lymphoproliferative disorders • Heavy Chain disease • Amyloidosis

  3. Patient Profile • 61 year old female presented with rash to dermatologists in 2001. SPEP revealed 0.2 IgGlambda M-protein. Asymptomatic otherwise. 2 Breast ca M-protein 1 2001 2002 2003 2004

  4. MGUS Denotes presence of an M-protein in a patient without a plasma cell or lymphoproliferative disorder • M-protein < 3g/dL • < 10% plasma cells in bone marrow • No or small amounts of M-protein in urine • Absence of lytic bone lesions,anemia,hypercalcemia or renal insufficiency • No evidence of B cell lymphoproliferative disorder • Stability of M-protein over time

  5. MGUS Monoclonal Gammopathy of Undetermined Significance • 1% of adults in US • 3% of adults over age 70 years • 11% of adults over age 80 years • 14% of adults over age 90 years

  6. MGUS MGUS can progress to monoclonal disease: IgA or IgG IgM Multiple Myeloma Primary Amyloidosis or related plasma cell disorder NHL CLL Waldentroms macroglobulinemia

  7. MGUS • 1,384 patients MGUS Light chain Heavy chain IgG : 70% IgM :15% IgA :12% Kappa : 61% Lambda : 39% Concentration of uninvolved immunoglobulins reduced in 39% Kyle, R. A. et al. N Engl J Med 2002;346:564-569

  8. MGUS prognosticators( predictors of progression): • Age • sex • Size of initial M-protein • Type of immunoglobulins • Hemoglobin • # of bone marrow plasma cells • Reduction of uninvolved imunoglobulins • Urinary light chains Kyle, R. A. et al. N Engl J Med 2002;346:564-569

  9. Initial Monoclonal Protein Values in 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy of Undetermined Significance Was Diagnosed from 1960 through 1994 Kyle, R. A. et al. N Engl J Med 2002;346:564-569

  10. Probability of Progression among 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy of Undetermined Significance (MGUS) Was Diagnosed from 1960 through 1994 Kyle, R. A. et al. N Engl J Med 2002;346:564-569 • Risk of progression to serious disease 1% per year

  11. Patterns of Increase in Monoclonal Protein among 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy Was Diagnosed in 1960 through 1994 Kyle, R. A. et al. N Engl J Med 2002;346:564-569

  12. MGUS • The size of the M-protein at the time of recognition of MGUS is the most important predictor of progression • IgM & IgA monoclonal proteins have a greater risk of progression than an IgG M-protein • Reduction in uninvolved immunoglobulins & urine protein not significant

  13. MGUS Management: • Periodic monitoring of serum protein electrophoresis • Interval of monitoring based on initial M-protein level • Monitoring should be at least annually LIFELONG • Risk does not go away with time “cumulative” probability of progression • ( 10% at 10 years , 25% at 25 years)

  14. Patient Profile • 64 year old female hospitalized with severe low back pain for 3 weeks. Spine films negative MRI scan showed path fracture at L2 . Fatigue x 2 months ESR: 28mm/hr Creat : 0.6 Calcium 9.4 SPEP : M-protein : IgG kappa 4.8 g/dl

  15. SPEP Multiple Myeloma 3-4 % patients have no serum or urine M-protein “non-secretory myeloma”

  16. Multiple Myeloma

  17. Patient Profile • Skeletal survey : diffuse osteoporosis • Bone marrow : 48% atypical plasma cells • L2 biopsy: plasmacytoma

  18. Multiple Myeloma Diagnostic definition: Minimal criteria for diagnosis include a bone marrow containing > 10% plasma cells (or plasmacytoma) plus at least one of the following: • M-protein in serum >3 g/dL • M-protein in urine • Lytic bone lesions

  19. Multiple Myeloma International Myeloma Working Group: • Presence of an M-protein in serum • Presence of bone marrow clonal plasma cells • Presence of related tissue or organ impairment (“CRAB”) C calcium R renal failure A anemia B bone lesions

  20. Multiple Myeloma Bone Disease Conventional radiographs abnormal 80% of patients who present with multiple myeloma Osteopenia or osteoporosis 20% Focal lytic bone 57%% Pathologic fractures 20% Vertebral body compression fractures 20%

  21. Multiple Myeloma MRI scan: • MRI scans of spine are an excellent assessment of bone marrow and myelomatous involvement. • >95% of patients with multiple myeloma have MRI abnormalities: Diffuse involvement of bone marrow Focal bone marrow lesions Heterogeneous bone marrow

  22. Multiple Myeloma Osteolytic lesions occur through 2 mechanisms via production of cytokines by myeloma cells adjacent to bone: Stimulation of osteoclastic activity IL-6 Inhibition of osteoblastic activity

  23. The Role of Wnt-Signaling Antagonist DKK1 on the development of Osteolytic Lesions in Multiple Myeloma Gene expression analysis NEJM Tian,E Dec 2003

  24. Multiple Myeloma Bone disease: mechanism for osteolytic lesions BM microenvironment Myeloma cell overexpress DKK1 Osteoclasts osteoblast Tian,EDec 2003 NEJM

  25. Multiple Myeloma Oncologic emergency Spinal cord compression occurs in 5 % of patients with multiple myeloma Managed with urgent: 1. Corticosteroids 2.neurosurgical intervention (laminectomy or anterior decompression) + radiation therapy to preserve neurological function 3. Radiation therapy alone

  26. Multiple Myeloma Normochromic /normocytic anemia occurs in 75% patients at diagnosis

  27. Multiple Myeloma Renal disease • Serum creatinine increased in > 50% at diagnosis • Creatinine >2g/dL in 20% of patients • Renal failure may be presenting manifestation Major causes: • Myeloma cast nephropathy • Hypercalcemia • Amyloidosis • Radiocontrast dye in a patient with myeloma

  28. Multiple Myeloma

  29. Multiple Myeloma

  30. Multiple Myeloma Prognosticators: • Serum beta2 microglobulin- small protein synthesized by all nucleated cells;light chain moiety of HLA antigen • LDH reflects cell turnover • C-reactive protein reflects IL-6 levels

  31. Multiple Myeloma • Cytogenetics Abnormalities associated with chromosome 13 carry a particularly unfavorable prognosis & respond poorly to therapy

  32. Multiple Myeloma Management MGUS Multiple myeloma SMM SMM –smoldering multiple myeloma : M-protein >3g/dl ,bone marrow plasma cells >10%, but asymptomatic with no organ related problems SMM requires no intervention but close surveillance to assess stability

  33. Multiple Myeloma • Treatment:Bisphosphonates: Pamidronate given monthly IV has been demonstrated to significantly reduce skeletal events in patients with Multiple Myeloma. Pamidronate* Placebo Skeletal events 21% 41% • Also reduces bone pain

  34. Multiple Myeloma Management Multiple Myeloma Age <70 Transplant eligible Age > 70 Transplant ineligible Melphalan 0.15mg/kg x 7 d Prednisone 20mg po tid x 7d MP produces reponse rates of 50-60% & median survival of 2-3 years

  35. Multiple Myeloma Conventional chemotherapy for induction: VAD -Vincristine Adriamycin Dexamethasone ORR CR* 84% 27% Modification of this regimen now with VDD(pegylated lipasomal doxirubicin) *Anderson,H:Br J Cancer 1995

  36. Multiple Myeloma Thalidomide • old drug 1950’s for sedation & pregnancy induced nausea/vomiting • Withdrawn 1961-tetratogenic causing phocomelia • Deformities later found to be due to inhibition of developing fetal limbs vessels (anti-angiogenic) IMiDs (immunomodulatory agent )with antiangiogenic properties

  37. Multiple Myeloma Thalidomide & dexamethasone • Myeloma patients with refractory disease underwent clinical trials producing 50% response rate (CR =PR ) • Median survival from start of therapy 38 months • Relatively minor side effects and taken orally • Major clinical trials now testing thalidomide /Dex as induction regimen

  38. Multiple Myeloma Proteosome inhibitors (Velcade) FDA approval May 2003 Interferes with intracellular pathway that degrades proteins regulating cell cycle, apoptosis,angiogenesis

  39. Multiple Myeloma • Autologous transplantation – recommended for advanced stage myeloma after induction therapy = age <70, good PS, normal renal function Tandem double better than single (41 vs 21 mos OS) • Allogeneic transplantation-insufficient evidence currently nonmyeloblative “mini” transplants as salvage

  40. Poems(osteosclerotic myeloma) • Polyneuropathy dominating feature(100%),motor • Organomegaly-hepatosplenomegaly (50%) • Endocrinopathy hypogonadism, hypothyroidism (66%) • Monoclonal gammopathy • Skin changes hyperpigmentation, hypertrichosis Sclerotic bone lesions –97% Etiology of symptoms related to proinflammatory cytokines (VEGF)

  41. Poems(osteosclerotic myeloma) Treatment : 5000cGy to osteosclerotic bone lesion

  42. Patient Profile • 54 year old high profile male trial attorney went skiing with the “firm” in March 2002. Fell & fractured left humerus. Saw orthopedic surgeon on return to Dallas.”Pathologic fracture”bone survey otherwise negative: MRI spine negative. Lab: BM : <10% plasma cells SPEP 0.52% IgGkappa UPEP -negative DX : Solitary Plasmacytoma left humerus

  43. Solitary plasmacytoma • Presence of single plasmacytoma without evidence of multiple myeloma • Younger median age at presentation (55yrs) • 50-60% will convert multiple myeloma within 10 years • Treatment: tumoricidal radiation to site (5000cGy) • Possible bone marrow collection/storage

More Related